Literature DB >> 15835512

Guidelines for the medical management of Irish children and adolescents with Down syndrome.

J Murphy1, H M C V Hoey, M Philip, E F Roche, S Macken, P Mayne, D Duff, M O'Keefe, D McShane, E Fogarty, M O'Regan.   

Abstract

Down syndrome (DS) is the most common chromosomal cause of developmental disability in Ireland. Children with DS have a high incidence of associated treatable medical disorders where early intervention carries a better outcome. Currently there are no agreed protocols for the screening and management of children and adults with DS in Ireland. A cross-sectional study of 394 children and adolescents was undertaken in the Eastern Regional Health Authority (ERHA) to assess the medical needs of children and adolescents with DS, in order to develop medical management guidelines. This study provides evidence-based data that children and adolescents with DS have a high incidence of treatable medical disorders, which supports the need for the medical management guidelines presented.

Entities:  

Mesh:

Year:  2005        PMID: 15835512

Source DB:  PubMed          Journal:  Ir Med J        ISSN: 0332-3102


  4 in total

1.  Down syndrome, insulin-dependent diabetes mellitus and hyperthyroidism: a rare association.

Authors:  Inês Marques; Ana Silva; Sofia Castro; Lurdes Lopes
Journal:  BMJ Case Rep       Date:  2015-06-29

Review 2.  Oxidative stress, thyroid dysfunction & Down syndrome.

Authors:  Carlos Campos; Ángela Casado
Journal:  Indian J Med Res       Date:  2015-08       Impact factor: 2.375

3.  Low Rates of Preventive Healthcare Service Utilization Among Adolescents and Adults With Down Syndrome.

Authors:  Kristin M Jensen; Elizabeth J Campagna; Elizabeth Juarez-Colunga; Allan V Prochazka; Desmond K Runyan
Journal:  Am J Prev Med       Date:  2020-11-12       Impact factor: 5.043

4.  Postcataract surgery outcome in a series of infants and children with Down syndrome.

Authors:  C Gardiner; B Lanigan; M O'Keefe
Journal:  Br J Ophthalmol       Date:  2008-08       Impact factor: 4.638

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.